64 related articles for article (PubMed ID: 26614420)
1. Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.
Samson P; Crabtree TD; Robinson CG; Morgensztern D; Broderick S; Krupnick AS; Kreisel D; Patterson GA; Meyers B; Puri V
Ann Thorac Surg; 2017 Apr; 103(4):1070-1075. PubMed ID: 28110809
[TBL] [Abstract][Full Text] [Related]
2. Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.
Deng H; Liu J; Cai X; Jiang S; Lu W; Ai Q; Li J; Xiong S; Qin X; Liang W; He J
BJS Open; 2024 Mar; 8(2):. PubMed ID: 38513281
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for recurrence-free survival in resected pathologic N2-stage III non-small cell lung cancer treated with upfront surgery.
Tsai PC; Liu C; Yeh YC; Hsu PK; Huang CS; Hsieh CC; Hsu HS
J Chin Med Assoc; 2024 Feb; 87(2):212-218. PubMed ID: 38156883
[TBL] [Abstract][Full Text] [Related]
4. External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.
Farjah F; Backhus LM; Varghese TK; Manning JP; Cheng AM; Mulligan MS; Wood DE
J Thorac Dis; 2015 Apr; 7(4):576-84. PubMed ID: 25973222
[TBL] [Abstract][Full Text] [Related]
5. Appropriateness of imaging for lung cancer staging in a national cohort.
Backhus LM; Farjah F; Varghese TK; Cheng AM; Zhou XH; Wood DE; Kessler L; Zeliadt SB
J Clin Oncol; 2014 Oct; 32(30):3428-35. PubMed ID: 25245440
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.
Wong LY; Liou DZ; Roy M; Elliott IA; Backhus LM; Lui NS; Shrager JB; Berry MF
JTO Clin Res Rep; 2024 Mar; 5(3):100654. PubMed ID: 38496376
[TBL] [Abstract][Full Text] [Related]
7. Comments on "Effect of Surgical Treatment for N2-Positive c-Stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era".
Ohri N; Chudgar NP; Vimolratana M; Cheng H; Stiles B
Clin Lung Cancer; 2024 Mar; 25(2):e75-e76. PubMed ID: 38057187
[No Abstract] [Full Text] [Related]
8. Long-Term Outcomes of Selected Patients with IIIA-N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection.
Fu F; Sun W; Bai J; Deng C; Zheng D; Li Y; Zhang Y; Chen H
Ann Surg Oncol; 2023 Dec; 30(13):8261-8270. PubMed ID: 37644250
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of [
Zhang L; E H; Huang J; Wu J; Li Q; Hou L; Li C; Dai C; Deng J; Yang M; Ma M; Ren Y; Luo Q; Zhao D; Chen C
Eur Radiol; 2023 Dec; 33(12):8564-8572. PubMed ID: 37464112
[TBL] [Abstract][Full Text] [Related]
10. miR-26 Induces Apoptosis and Inhibits Autophagy in Non-small Cell Lung Cancer Cells by Suppressing TGF-β1-JNK Signaling Pathway.
He Y; Liu H; Jiang L; Rui B; Mei J; Xiao H
Front Pharmacol; 2018; 9():1509. PubMed ID: 30687089
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer.
Sher DJ
Front Oncol; 2017; 7():281. PubMed ID: 29255697
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the effect of nodal downstaging and its implication of the role of surgery in stage IIIA (N2) non-small cell lung cancer.
Martin LW; Mehran RJ
J Thorac Dis; 2017 Jul; 9(7):E646-E652. PubMed ID: 28840035
[No Abstract] [Full Text] [Related]
15. N2-IIIA non-small cell lung cancer: a plea for surgery!
Massard G; Renaud S; Reeb J; Santelmo N; Olland A; Falcoz PE
J Thorac Dis; 2016 Nov; 8(Suppl 11):S849-S854. PubMed ID: 27942406
[TBL] [Abstract][Full Text] [Related]
16. Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective†.
Rocco G; Nason K; Brunelli A; Varela G; Waddell T; Jones DR
Eur J Cardiothorac Surg; 2016 Apr; 49(4):1025-7. PubMed ID: 26985072
[No Abstract] [Full Text] [Related]
17. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
